MEAI
MEAI is a recreational drug and binge drinking prevention drug, first chemically described in 1980, and first pharmacologically described in a peer reviewed paper in 2017 by David Nutt et al., followed by another in February 2018 which detailed pharmacokinetics, pharmacodynamics and metabolism of MEAI. In 2018, a company in the United States began offering an MEAI-based drink called "Pace".
MEAI was an early candidate of alcohol replacement drugs that came to market during a late 2010s movement to replace alcohol with less-toxic alternatives spearheaded by British psychopharmacologist David Nutt. Though MEAI was made commercially available online in the United States as "Pace", Nutt's commercial efforts moved away from direct marketing of MEAI in favor of Alcarelle.
